Cell Cryopreservation Market Size, Share, and Industry Analysis, By Product Type (Cryopreservation Media, Equipment/Cryopreservation Systems, and Consumables), By Cell Type (Stem Cells {Mesenchymal Stem Cells, Hematopoietic Stem Cells, and Pluripotent Stem Cells}, Immune Cells, and Reproductive Cells), By Application (Cell Therapy Manufacturing, Biobanking, Research & Drug Discovery, and IVF/Reproductive Medicine), By End User (Biopharmaceutical Companies, Biobanks/Cell Banks, Academic & Research Institutes, and Fertility Clinics), and Regional Forecast till 2034

The global cell cryopreservation market was valued at USD 1.20 billion in 2025. The market is projected to grow from USD 1.34 billion in 2026 to USD 3.20 billion by 2034, exhibiting a CAGR of 11.5% during the forecast period.

The global market is poised for significant growth as the demand for preserved cells is increasing for key applications across cell therapy manufacturing, biobanking, fertility preservation, regenerative medicine, and research applications. As the use of stem cells, immune cells, reproductive cells, and other specialized cells increases across research workflows, companies and laboratories are adopting reliable solutions to maintain cell viability. The market is also gaining momentum as cell and gene therapy programs move from research into clinical and commercial manufacturing. Overall, the market is supported by the need to protect high-value biological materials, reduce cell loss, improve reproducibility, and ensure consistent quality across the complete cryopreservation workflow.

Underscoring the growth potential of the market, key companies are directing their resources toward new product development and strategic collaborations to capitalize on market growth.

• For instance, in April 2025, BioLife Solutions acquired PanTHERA CryoSolutions to strengthen its cryopreservation technology portfolio. PanTHERA designs cryopreservation solutions for cells, tissues, and organs, and its patented ice recrystallization inhibition technology is intended to improve cell recovery and quality after freezing.

Furthermore, funding initiatives, technological advancements, strategic partnerships, and new product launches are carried out by key operating companies to strengthen their market position and support global market growth.

Cell Cryopreservation Market Driver

Rising Adoption of Stem Cell Banking and Regenerative Medicine to Support Market Growth

One of the prominent factors driving the growth of the global cell cryopreservation market is the soaring adoption of stem cell banking for regenerative medicine. They require safe, long-term preservation of high-value living cells. Stem cells need to remain viable and functional after undergoing a series of processes, which increases the demand for specialized cryopreservation media, controlled freezing systems, cryogenic storage solutions, and cell banking services. As more companies and healthcare providers focus on stem cell-based therapies, personalized biologics, and regenerative treatment models, the need for reliable cryopreservation workflows continues to rise.

• For instance, in June 2026, AcCELLerated Biologics partnered with Forever Labs to advance stem cell storage and regenerative medicine solutions. The partnership aimed to combine the company’s regenerative medicine platform with Forever Labs’ adult stem cell banking, cryopreservation, and expansion capabilities.

Download Free sample to learn more about this report.

For instance, in February 2026, Frontiers in Pharmacology published an article titled ‘Global Panoramic analysis of clinical research in cell therapy: clinical trial landscape, marketed products, and regulatory trends’. The article reported that a cumulative total of 10,373 cell therapy clinical trials were identified worldwide, with primary distribution across the U.S. (3,563 trials), China (3,365 trials), and Europe (1,584 trials). Such increasing clinical trials are elevating the demand for the cell cryopreservation market and driving market growth.

Cell Cryopreservation Market Restraint

Risk of Cell Viability Loss During Freezing, Storage, Transportation, and Thawing to Restrain Market Growth

The risk of cell viability loss during freezing, storage, transportation, and thawing is a key restraint faced by the market. As living cells lose viability and functionality when freezing, storage, transportation, or thawing occur under conditions that are not properly controlled. Sensitive cells such as stem cells, immune cells, and cell therapy products can be damaged by ice crystal formation, osmotic stress, cryoprotectant toxicity, temperature fluctuations, and improper thawing practices. Further, gaps in cell therapy manufacturing, storage, handling, and finished drug product controls can disrupt clinical programs and increase the need for validated cryopreservation workflows, controlled storage conditions, and stronger product-quality documentation. This creates a challenge for biopharmaceutical companies given that poor post-thaw recovery can reduce usable cell yield, delay manufacturing workflows, and increase the cost of cell-based programs.

• For instance, in May 2025, Atara Biotherapeutics announced that the U.S. FDA lifted the clinical hold on its EBVALLO/tabelecleucel program. Still, they stated that the January 2025 hold was directly linked to GMP compliance issues identified during the pre-license inspection of a third-party manufacturing facility. Such instances highlight the need for validated cryopreservation workflows, controlled storage conditions, and stronger product-quality documentation.

Cell Cryopreservation Market Opportunity

Expansion of Cell and Gene Therapy Manufacturing to Create Demand for Clinical-grade Cryopreservation Solutions

The rising scale-up of cell and gene therapy manufacturing is creating a strong opportunity for the global cell cryopreservation market. As more advanced therapies move from early research to late-stage trials and commercial production, manufacturers need reliable freezing media, controlled-rate freezers, cryogenic storage systems, frozen transportation, and thawing solutions to protect high-value living cells across the full workflow. These factors create a direct opportunity for suppliers given that clinical-grade cryopreservation products help maintain cell viability, reduce batch-to-batch variability, support GMP compliance, and improve the consistency of therapy manufacturing. Such factors are encouraging key companies to expand their manufacturing capabilities to cater to the increasing product demand.

• For instance, in May 2025, Made Scientific expanded its 12,000 sq. ft. GMP facility in Princeton, New Jersey, to support late-phase and commercial cell therapy manufacturing. The expansion is anticipated to cater to the rising need for scalable infrastructure.

Segmentation

Key Insights

The report covers the following key insights:

• Overview of Advanced Cryopreservation Technologies and Controlled Freezing Platforms
• Regulatory Scenario, By Key Countries/Regions
• New Product Launches and Indication Expansions, By Key Players
• Key Industry Developments (Mergers, Collaborations, and Acquisitions)

Analysis by Product Type

Based on product type, the global cell cryopreservation market is segmented into products, instruments/ cryopreservation systems, consumables, and services.

The products segment is expected to dominate the market as freezing media, cryoprotectants, and preservation reagents are used in almost every cryopreservation cycle. As cell therapy, stem cell research, and biobanking activities increase, laboratories and manufacturers need repeated purchases of media and reagents to protect cells from freezing damage and maintain post-thaw recovery. This creates a recurring revenue base. Furthermore, new product launches and regulatory approvals further support segment growth.

• For instance, in March 2025, CaseBio Culture and CaseBio Handling Media received FDA 510(k) clearance for clinical use, marking a milestone for CaseBioscience and its ART portfolio. CaseBio Culture has undergone extensive preclinical testing, including multi-generation mouse embryo transfer studies and additional mammalian models, prior to launch, establishing an unprecedented standard of safety, effectiveness, and evidence-based validation in reproductive medicine.

Analysis by Cell Type

Based on cell type, the market is segmented into stem cells, immune cells, reproductive cells, and others.

The stem cells segment is likely to account for the largest share. They are used across multiple high-value applications, including regenerative medicine, cord blood banking, pluripotent stem cell research, and cell therapy development. Stem cells are sensitive biological materials and poor freezing or thawing can affect viability, differentiation potential, and downstream usability. This creates strong demand for specialized cryopreservation solutions, leading to segmental growth.

• For instance, in July 2025, NextCell collaborated with FUJIFILM Biosciences to provide researchers and cell therapy developers with an integrated offering that includes standardized MSC products, optimized culture media, and cryopreservation solutions. The development highlights the growing commercial focus on stem cell-specific preservation workflows.

Analysis by Workflow Stage

Based on workflow stage, the market is segmented into cell collection & preparation, freezing, frozen storage, frozen transportation, thawing & recovery, and inventory monitoring.

The frozen storage segment dominates the cell cryopreservation market. Cells are often preserved for months or years before being used in research, manufacturing, IVF, or clinical applications, which is a key factor propelling segment dominance. Once cells are frozen, they require stable storage conditions, sample tracking, and temperature monitoring to prevent loss of viability and sample mix-ups. As the number of cell therapy programs, biobanks, and biological repositories grows, the need for long-term cryogenic storage infrastructure also increases, supporting the dominance of frozen storage.

• For instance, in August 2025, Minaris Advanced Therapies opened a new GMP manufacturing facility in Munich, Germany. The site includes cryopreservation and storage facilities. The development reinforced its position as a leading player in advancing cutting-edge therapies to commercialization.

Analysis by Grade

Based on grade, the market is segmented into clinical, research, and others.

The research segment is expected to dominate the market given that research laboratories and early-stage biopharma R&D groups use cryopreservation products widely for routine cell culture, drug screening, assay development, and disease modeling. Clinical-grade products are growing quickly due to cell therapy manufacturing. Still, research-grade products are used by a much larger number of laboratories and across a broader range of cell types. This wider adoption base allows research-grade products to remain the largest segment by volume and overall value.

• For instance, in April 2024, Pluristyx launched PluriFreeze cryopreservation media to accelerate stem cell therapy development. The product supports cellular therapy development, showing how research and development users continue to require specialized freezing media before products move into larger clinical workflows.

Analysis by Application

Based on application, the cell cryopreservation market is segmented into cell therapy manufacturing, biobanking, research & drug discovery, IVF/reproductive medicine, and others.

The biobanking segment is anticipated to hold a dominant share. This dominance is as biobanks preserve cells and biological samples for long-term research, clinical, fertility, and therapeutic use. Biobanking requires freezing media, consumables, and cryogenic storage systems, inventory monitoring, and sample management services. As more healthcare and life science organizations store high-value biological samples for future use, cryopreservation becomes a critical part of biobank operations, which supports the segment’s leading position.

• For instance, in February 2025, Charles River collaborated with Singapore General Hospital to support cGMP-compliant master cell banking and next-generation sequencing services. The development highlighted Charles River’s cGMP-compliant cell bank production and storage services, showcasing the importance of cell banking infrastructure in advanced therapy and biologics programs.

Analysis by End User

Based on end user, the market is segmented into hospitals & health systems, life sciences companies, payers, research institutes/data networks, and others.

The biopharma companies segment is expected to dominate the cell cryopreservation market. They need cryopreservation across discovery, process development, clinical trials, and commercial cell therapy manufacturing. These companies typically require high-quality media, validated freezing systems, cryogenic storage, cold-chain support, and documentation to protect cell quality and meet regulatory expectations. As more cell and gene therapy programs move toward late-stage and commercial manufacturing, biopharma companies are expected to remain the largest buyers by value.

• For instance, in January 2025, Terumo Blood and Cell Technologies and FUJIFILM Irvine Scientific announced collaboration progress around cell therapy workflow solutions, with FUJIFILM noting that its PRIME-XV T cell media has a Drug Master File to support therapeutic development. This shows how suppliers are building regulated workflow solutions for biopharma and cell therapy developers.

Regional Analysis

Request for Customization   to gain extensive market insights.

On the basis of region, the market has been analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 40.0% of the global cell cryopreservation market in 2025. The regional market is growing as the region has a strong base of cell therapy developers, biopharma companies, clinical trial sites, biobanks, and advanced therapy manufacturing facilities. The increased demand for high-quality cryopreservation solutions is driving growth. The region’s strong focus on automation, GMP manufacturing, and clinical-scale cell therapy production further supports the adoption of advanced cryopreservation products and services.

• For instance, in March 2026, ImmunityBio established a large-scale NK cell manufacturing and cryo-banking process from more than 60 healthy and cancer donors. The M-ceNK cells were successfully cryopreserved and retained cytotoxicity against multiple tumor cell lines. This highlights the growing need for scalable cryopreservation workflows in immune-cell therapy development.

The Europe market is expected to grow at a significant CAGR during the forecast period. The market in Europe is growing as the region expands its advanced therapy manufacturing network and strengthens GMP-compliant infrastructure for autologous and allogeneic cell therapies. European CDMOs and therapy developers are investing in cleanrooms, process development labs, storage, and cold-chain logistics as cell therapy products require controlled freezing, long-term storage, and traceable handling before clinical or commercial use. These factors directly support regional growth.

• For instance, in April 2025, Cell-Easy expanded its GMP cell therapy manufacturing facility in Toulouse, France, to support growing client demand. The upgrade included five Grade B cleanrooms, advanced process development laboratories, and a reengineered warehouse with gaseous LN2 storage for enhanced cell preservation. Such developments are showing how European cell therapy infrastructure is creating demand for cryogenic storage and cryopreservation workflows.

The Asia Pacific market is expected to grow at a stable CAGR during the forecast period. The regional market is witnessing expanding cell therapy development, regenerative medicine research, and clinical manufacturing capacity. This, in turn, is driving the demand for reliable freezing media, GMP-compliant cryopreservation, cryogenic storage, and frozen logistics. This creates strong growth potential. Key companies are focusing on expanding their manufacturing capabilities for cell cryopreservation, driving regional market growth.

• For instance, in June 2025, AGC Biologics expanded cell therapy process development and clinical manufacturing services at Yokohama Technical Center. The development marked a crucial step in the global expansion of the company’s Global Cell and Gene Technologies Division.

Key Players Covered

The global cell cryopreservation market is moderately fragmented but increasingly consolidating.

The report includes the profiles of the following key players.

• Thermo Fisher Scientific Inc. (U.S.)
• BioLife Solutions, Inc. (U.S.)
• Danaher Corporation (U.S.)
• Cryoport, Inc. (U.S.)
• Merck KGaA (Germany)
• Corning Incorporated (U.S.)
• STEMCELL Technologies Inc. (Canada)
• Sartorius AG (Germany)
• FUJIFILM Biosciences (U.S.)
• Azenta Life Sciences (U.S.)

Key Industry Developments

• February 2026: Cryoport, Inc. launched the MVE Fusion 800 Series. The self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN₂) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments.
• November 2025: Evia Bio launched CellShieldTM MSC, their first proprietary cryopreservation solution that enabled MSC-based therapy developers to generate equivalent or better performance compared to traditional, DMSO – based media.